This inventor holds 1 USPTO granted patent and 6 published patent applications. Top assignee: Fred Hutchinson Cancer Center. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Soheil Meshinchi: Innovator in Cancer Treatment
Introduction
Soheil Meshinchi is a prominent inventor based in Seattle, WA, known for his significant contributions to cancer treatment. He has developed innovative solutions aimed at targeting specific cancer types, particularly those expressing mesothelin.
Latest Patents
Soheil Meshinchi holds a patent for "Anti-mesothelin antigen-binding molecules and uses thereof." This patent focuses on mesothelin (MSLN), which is expressed in pancreatic cancers, ovarian cancers, and mesotheliomas. The disclosed antigen-binding molecules, including anti-MSLN antibodies and bispecific antigen-binding molecules, are designed to bind to both MSLN and a T cell antigen, such as CD3. This binding activates T cells in the presence of MSLN-expressing tumor cells. The molecules are particularly useful for treating diseases where a MSLN-targeted immune response is beneficial, including various cancers.
Career Highlights
Soheil Meshinchi is affiliated with the Fred Hutchinson Cancer Center, where he continues to advance research in cancer therapies. His work has the potential to significantly impact the treatment landscape for patients suffering from aggressive cancers.
Collaborations
Soheil collaborates with notable colleagues, including Colin Correnti and Ashok Bandaranayake, to further enhance the development of innovative cancer treatments.
Conclusion
Soheil Meshinchi's work exemplifies the intersection of innovation and healthcare, particularly in the fight against cancer. His contributions through patented technologies are paving the way for more effective treatments for patients facing challenging diagnoses.